|
Market Closed -
Canadian Securities Exchange
22:17:32 20/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.005000 CAD | -50.00% |
|
0.00% | -91.67% |
Company Valuation: RAMM Pharma Corp.
Data adjusted to current consolidation scope
| Fiscal Period: October | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 54.85 | 57.4 | 24.48 | 5.969 | 1.194 | 1.791 |
| Change | - | 4.66% | -57.35% | -75.61% | -80% | 50% |
| Enterprise Value (EV) 1 | 26.94 | 40.28 | 15.39 | 1.258 | 0.5682 | 1.067 |
| Change | - | 49.51% | -61.79% | -91.83% | -54.83% | 87.86% |
| P/E | -7.44x | -7.1x | -1.17x | -0.78x | -0.07x | -0.2x |
| PBR | 1.53x | 1.02x | 0.69x | 0.2x | 0.09x | 0.31x |
| PEG | - | 0.6x | -0x | 0x | -0x | 0x |
| Capitalization / Revenue | 10.1x | 13.9x | 6.28x | 1.18x | 0.27x | 0.53x |
| EV / Revenue | 4.95x | 9.79x | 3.95x | 0.25x | 0.13x | 0.32x |
| EV / EBITDA | -3.72x | -6.71x | -2.2x | -0.21x | -0.07x | -0.27x |
| EV / EBIT | -3.56x | -6.06x | -1.94x | -0.18x | -0.06x | -0.24x |
| EV / FCF | -14.3x | -8.01x | -4.06x | -0.54x | -0.2x | 1.04x |
| FCF Yield | -6.98% | -12.5% | -24.7% | -184% | -504% | 96.2% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0739 | -0.0655 | -0.1707 | -0.0638 | -0.1382 | -0.0746 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 5.445 | 4.116 | 3.897 | 5.065 | 4.342 | 3.361 |
| EBITDA 1 | -7.235 | -6.007 | -7.003 | -6.037 | -7.967 | -3.929 |
| EBIT 1 | -7.576 | -6.642 | -7.937 | -7.086 | -8.938 | -4.531 |
| Net income 1 | -7.431 | -7.107 | -20.96 | -7.721 | -16.5 | -8.91 |
| Net Debt 1 | -27.91 | -17.12 | -9.09 | -4.712 | -0.6257 | -0.7235 |
| Reference price 2 | 0.550000 | 0.465000 | 0.200000 | 0.050000 | 0.010000 | 0.015000 |
| Nbr of stocks (in thousands) | 99,723 | 123,449 | 122,400 | 119,389 | 119,389 | 119,389 |
| Announcement Date | 3/1/21 A | 3/22/22 A | 2/28/23 A | 2/29/24 A | 3/4/25 A | 3/5/26 A |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 427K | |
| 37.06x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.49x | 18.27x | 2.02% | 635B | |
| 36.46x | 8.38x | 17.29x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.68x | 13.94x | 2.81% | 295B | |
| 22.43x | 4.53x | 12.94x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 29.50x | 7.04x | 18.69x | 2.12% | 400.37B | |
| Weighted average by Cap. | 35.23x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RAMM Stock
- Valuation RAMM Pharma Corp.
Select your edition
All financial news and data tailored to specific country editions
